Compare BIO-TECHNE Corp (TECH) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Verizon Communications Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Verizon Communications Inc trades at $47.24 (market cap $195.40B). The key difference: Verizon Communications Inc is far larger — about 17.4× BIO-TECHNE Corp's market cap, and Verizon Communications Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals.
| TECH | VZ | |
|---|---|---|
Market Cap | $11.24B | $195.40B |
Sector | Health | Media |
52-Week High | $72.29 | $51.38 |
52-Week Low | $43.31 | $38.40 |
Enterprise Value | $11.32B | $382.11B |
Dividend Yield | 0.44% | 6.02% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Verizon (VZ) trades at $47.06, up 0.15% on the day, with a bullish technical signal and strong fundamentals including a P/E of 12.26 and a 6%+ dividend yield. Recent quarterly earnings have consistently beaten estimates, and cash flow from operations remains robust at $37.14 billion for 2025. The company is shifting focus to broadband growth and AI infrastructure, highlighted by a major dark fiber deal with Alphabet.
Outlook is positive with a consensus price target of $49.69, though competitive threats from SpaceX's Starlink and high debt levels pose risks. The stock offers value and income appeal, supported by analyst buy ratings and institutional accumulation, but investors must weigh growth initiatives against sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
